FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2359-2361 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Strategies for Management of Antiretroviral Therapy (SMART) Study Group PubMed Citation

Soon after the benefits of potent combination antiretroviral therapy were recognized in the late 1990s,¹ clinicians understood that patients would need to be highly adherent to antiretroviral therapy and treated continuously with combination regimens. If this mark were not met, there was a real likelihood that a resistant virus would emerge. As experience with combination regimens expanded, data became available on long-term toxic effects, including dyslipidemia, changes in body fat, possibly increased cardiovascular risk, and hepatitis.^2,3,4 Although infection with the human immunodeficiency virus (HIV) became a more manageable chronic disease, concerns about side effects led both patients and investigators to . . . [Full Text of this Article]

Source Information

From the University of California, Los Angeles (J.S.C.).

This article has been cited by other articles:

• Foster, C., Lyall, H. (2008). HIV and mitochondrial toxicity in children. J Antimicrob Chemother 61: 8-12 [Abstract] [Full Text]  
• (2006). Episodic HIV Treatment: Not a SMART Idea. JWatch Infect. Diseases 2006: 1-1 [Full Text]  
• (2006). Intermittent HIV Treatment Fails Dramatically. AIDS Clin Care 2006: 1-1 [Full Text]  
• (2006). Treating HIV Infection with Intermittent Antiretrovirals Fails. JWatch General 2006: 3-3 [Full Text]